Post-Marketing Surveillance of Micombi Tablets Survey on the Long-term Use

NCT01050062 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1452

Last updated 2014-05-01

Study results available
· View outcomes & findings →

Summary

The survey is conducted to collect safety and effectiveness information in Hypertensive patients treated with Micombi Tablets on the long term use in daily clinical settings in Japan.

Conditions

Interventions

DRUG

Telmisartan 80mg

Combination tablet

DRUG

Telmisartan 40mg

Combination tablet

DRUG

Hydrochlorothiazide 12.5mg

Combination tablet

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01050062 on ClinicalTrials.gov